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CONTRIBUTION OF THE SYMPATHETIC NERVOUS SYSTEM TO THE 
PATHOGENESIS OF SALT-SENSITIVE HYPERTENSION 
MICHAEL LEE PAZZOL 
ABSTRACT 
Dysregulation of the sodium-chloride cotransporter (NCC) is believed to 
significantly impact blood pressure. Recent studies have implicated overactivity of the 
sympathetic nervous system as a mechanism driving renal NCC dysregulation to evoke 
the development of salt-sensitive hypertension. It is proposed that the sympathetic 
nervous system accomplishes this by norepinephrine (NE)-mediated over-activation of 
the beta2-adrenergic receptors located in the distal tubules of the kidney. Beta2-
adrenoreceptor activation is hypothesized to stimulate the protein kinases SPAK and 
OxSR1 to phosphorylate and thus activate NCC. This beta2-receptor-SPAK/OxSR1-NCC 
pathway was elucidated in studies that challenged salt-resistant mice with high-salt diets, 
bilateral adrenalectomies, and NE infusion. To expand the scope of these studies, we 
investigated the effects of elevated circulating NE on blood pressure, NCC activity, and 
expression of NCC proteins, SPAK, and OxSR1 in a different salt-resistant animal 
species (the Sprague-Dawley rat).  
 In this study we implanted male Sprague-Dawley rats with osmotic minipumps 
delivering a subcutaneous infusion of either saline, NE, a 50:50 solution of 
DMSO/isotonic saline, a combination of NE and the NCC antagonist 
hydrochlorothiazide, or a combination of NE and the beta-adrenoreceptor antagonist 
propranolol. Following implantation of the pumps the rats were randomly assigned to 
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either a standard diet (0.4% NaCl) or a high-salt diet (8% NaCl) for two weeks. After 
fourteen days all animals underwent acute femoral artery, vein, and bladder cannulation 
in order to monitor heart rate and blood pressure, administer drugs intravenously, and 
track renal function, respectively. Following surgical recovery, blood pressure and heart 
rate were measured continuously, and urine was collected in ten-minute intervals in order 
to assess peak natriuretic responses to amiloride and hydrochlorothiazide. Following this 
protocol the rats received an intravenous bolus of hexamethonium (30 mg/kg), and their 
peak drops in blood pressure were recorded. Afterwards both kidneys were harvested and 
frozen at -80 °C for measurement of NCC proteins, SPAK, and OxSR1 expression. 
 This study demonstrates that increased circulating NE induces salt-sensitive 
hypertension in the naturally salt-resistant Sprague-Dawley rat. Chronic infusion of NE 
raised the blood pressure of the rats, and a high-salt diet exacerbated this effect. 
Furthermore, NE prevented salt-evoked suppression of NCC activity and NCC, SPAK, 
and OxSR1 protein expression. Co-infusion of hydrochlorothiazide with NE attenuated 
NE-mediated hypertension and caused no variance in the blood pressures between the 
standard salt and high-salt groups. This indicates that chronically antagonizing NCC 
eliminated the salt-sensitive component of NE-mediated hypertension. Beta-receptor 
antagonism combined with NE infusion completely eliminated the hypertensive influence 
of NE and downregulated the expression of NCC proteins, SPAK, and OxSR1. However, 
NCC activity still remained at a level comparable with that observed in the NE-infused 
rats, demonstrating dissociation between protein expression and function.  
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 These data, the first report in a rat model of an interaction of NE and a high salt 
intake that impairs NCC function, demonstrate that increased levels of NE in 
combination with a high dietary salt intake result in NCC dysregulation and the 
development of NE-mediated salt-sensitive hypertension. To an extent the data also 
support the proposition that NE activates the beta-adrenergic receptors to influence the 
activity of NCC and the expression of NCC proteins, SPAK, and OxSR1. Beta-
antagonism combined with NE infusion attenuated the effects of NE on blood pressure 
and the expression of NCC proteins, SPAK, and OxSR1. However, the NE-mediated 
elevation of NCC activity still remained high. We propose that the beta-receptors are not 
the only adrenergic receptors that can influence NCC activity. The presence of alpha-
adrenergic receptors in the distal tubules suggests that they may be able to keep NCC 
activity elevated through a pathway independent of the beta-receptors, SPAK, and 
OxSR1.  
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INTRODUCTION 
 
Cardiovascular disease (CVD) is a global pandemic. While CVD was once a 
relatively minor disease, it has matured into the killer responsible for 30% of global 
deaths each year.1 Although its prevalence is high and its manifestation assumes the 
forms of numerous diseases, many of those who suffer from CVD share a commonality: 
high blood pressure.2 By increasing the chances of stroke, congestive heart disease, and 
heart failure, hypertension is a major risk factor of CVD. As of the year 2000, one billion 
of the world’s population had hypertension, with the number expected to rise to 1.56 
billion by 2025.1 In Western countries alone, 18% of CVD mortalities are a result of 
hypertension.3 In the United States, one-third of the adult population has hypertension, 
and half of those people will die from it. A fifth of them do not even know they have high 
blood pressure because of its asymptomatic nature. Even though antihypertensive therapy 
can decrease the risk of stroke by 30%, congestive heart failure by 40%-50%, coronary 
heart disease by 10%-20%, and overall mortality by 10%2, only half of those undergoing 
treatment succeed in lowering their blood pressure below the recommended threshold of 
140/90 mm Hg.4 The limitations of current treatment, coupled with the high economic 
burden of hypertension3, have created a drive to find cheaper, more efficacious 
treatments. 
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Salt Sensitivity 
Hypertension exists in various forms such as secondary, resistant, and pseudo-
resistant. While the pathogeneses of pseudo-resistant and secondary hypertension are 
known and treatable, the causes of resistant hypertension remain elusive.5 Resistant (also 
known as idiopathic or essential) hypertension is a blood pressure exceeding 140/90 mm 
Hg that refuses to drop despite being treated with three or more drugs (one of which is a 
diuretic) at maximum doses. Obesity, increasing age, and kidney disease are suspected of 
contributing to resistant hypertension, but the exact mechanisms remain unclear.6 Peaking 
the curiosity of researchers is that one of the most common traits in those with resistant 
hypertension is excessive salt consumption.5 This led to studies of how salt intake affects 
blood pressure. When experimenting on single individuals, researchers found a positive 
correlation between salt intake and blood pressure, but when they tested this correlation 
in large populations, it diminished.7 To account for this discrepancy, the theory of salt 
sensitivity was developed. For some individuals a high salt intake raises their blood 
pressure, but for others the excess salt only exerts marginal effects on pressure. The 
former group was called salt-sensitive (SS), and the latter group salt-resistant (SR).8   
  
The Pressure-Natriuresis Curve 
 To understand salt sensitivity, one must first understand sodium balance in an SR 
individual. Suppose an SR person eats a salty meal. The ingested sodium is absorbed into 
the blood stream. There it draws water from the cells into the extracellular fluid (ECF) 
space. This expansion of the ECF raises the cardiac output, blood pressure, and 
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subsequently the perfusion pressure on the kidney. The kidney responds twofold: it filters 
more sodium and water and reabsorbs less. Sodium and water excretion rises, and blood 
pressure returns to normal.9 What is present here then is a positive correlation between 
blood pressure and natriuresis. Graphing this relationship yields the pressure-natriuresis 
curve, and it helps us understand a potential contributor to salt-sensitive hypertension.10–
12  
 
 
Figure 1. Relationship between salt intake, blood pressure, and natriuresis. A: The 
equilibrium between pressure, sodium intake, and natriuresis in a salt-resistant individual. 
B: Increased salt intake in a salt-resistant individual. The slope steepens and shifts left. 
Natriuresis increases with little change in blood pressure. C: The equilibrium between 
pressure, sodium intake, and natriuresis in a salt-sensitive individual. The slope decreases 
and shifts right. More pressure is needed to excrete excessive sodium. MABP, mean 
arterial blood pressure. Figure taken from Mullins and Mullins.1.2  
 
Guyton, an early proponent of the pressure-natriuresis curve, hypothesized that 
chronic hypertension was not solely caused by high vascular resistance which was a 
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popular idea during his time. He believed factors that altered the position and slope of the 
pressure-natriuresis curve were culpable as well. These factors would be changes in salt 
intake and alterations in kidney function. In an SS person the pressure-natriuresis curve 
has shifted to the right, and the slope has decreased. This means that it takes a greater 
increase in blood pressure to excrete the same amount of sodium that an SR person 
excretes at a lower blood pressure. The physiological difference between SR and SS 
individuals is not in the extent of their natriuresis but in the efficiency with which they 
achieve it.7,10  
 
Kidney Sodium Transporters 
The decreased efficiency in sodium excretion present in SS individuals is 
attributed in part to overactivity of the sodium transporters in the kidney.13 These 
transporters and ion channels line the apical membranes of the tubular cells of the 
nephron in a non-uniform manner, thus granting each part of the nephron a unique 
reabsorption capacity. The proximal tubule (PT) is the site of bulk transport, reabsorbing 
60%-70% of the filtered sodium through the Na/H exchanger NHE3. Another 20%-30% 
is reabsorbed in the thick ascending limb (TAL) by the Na/K/2Cl cotransporter NKCC2. 
The final 5%-7% is reabsorbed in the distal tubule (DT) mostly by the Na/Cl 
cotransporter NCC but also by the epithelial sodium channel ENaC. The collecting duct 
(CD) performs last minute sodium adjustments primarily through ENaC.14  
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The Sodium-Chloride Cotransporter (NCC) 
Despite only reabsorbing a small fraction of the filtered sodium, overactivity of 
NCC may contribute to salt-sensitive hypertension.15 The NCC is a 12-transmembrane-
spanning homodimer which cotransports sodium and chloride in an electroneutral 1:1 
ratio.14,16 The influence of the NCC on blood pressure has been elucidated through 
observations of diseases that cause its over- and underexpression. Gordon’s syndrome 
(also known as pseudohypoaldosteronism type II (PHAII) or familial hyperkalemic 
hypertension (FHht)) is a genetic disease in which a mutation in the NCC regulatory 
pathway causes NCC overexpression. NCC activity rises, and elevated blood pressure, 
hypercalciurea, and hyperkalemic acidosis ensue. Conversely, mutations which decrease 
NCC activity cause hypotension, hypokalemia, and low calcium and magnesium levels in 
a disorder known as Gitelman’s syndrome.14,17 The response of NCC to thiazides is also 
noteworthy. Thiazides are some of the oldest and most efficacious diuretics used to treat 
hypertension, and they do so by blocking NCC.18 However, they are only effective in 
hypertensive patients (such as those with Gordon’s syndrome).19 Their effect on 
normotensive patients is negligible at best. These findings suggest that NCC possesses a 
substantial influence on blood pressure.15 
 While thiazides have their benefits, they also induce multiple side effects such as 
hypercalcinemia, hypokalemia, and insulin resistance.14 If a drug could target NCC with 
greater precision, it may achieve a greater antihypertensive effect while forgoing the side 
effects. The fact that Gordon’s and Gitelman’s syndromes are caused by 
activating/inactivating mutations in the regulatory pathway has sparked further research 
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into how NCC makes its way to the apical membrane and what molecules regulate this 
process. It was found that NCC is transcribed from the gene SLC12A3, processed in the 
endoplasmic reticulum and Golgi apparatus, and shipped to the plasma membrane. There 
it is activated by phosphorylation. This presents two areas for regulation: the amount of 
NCC expressed on the apical membrane (Type 1) and the level of its phosphorylation 
(Type 2).14 These processes are regulated by a series of kinases that constitutes the 
WNK-SPAK/OxSR1-NCC kinase chain.20  
  
WNKs 
The most upstream kinases of this pathway are the With-No-Lysine (WNK) 
kinases. They exist all over the body and serve various functions. In the kidney they 
regulate NCC, ENaC, NKCC2, and ROMK (renal outer medullary potassium channel).18 
Their activation is brought about through self-phosphorylation. How exactly they know 
when to self-phosphorylate is unclear, but low intracellular chloride, hyperosmotic 
conditions, and decreased cell volume seem to promote it. Once the WNKs are 
phosphorylated, their N-terminal regions RFXV/I bind to the unique conserved C-
terminals in the downstream kinases SPAK (STE20/SPS1-related proline/alanine-rich 
kinase) and OxSR1 (serine/threonine-protein kinase) and phosphorylate key threonine 
residues (Thr233 in SPAK, Thr185 in OxSR1). This encourages SPAK and OxSR1 to 
bind to the peptide motif RFXV/I in the N-terminal region of NCC, phosphorylate Thr53, 
Ser71, and T58, and thus activate NCC.20,21 Degradation of WNKs is mediated by the 
ubiquitin E3 ligase. Two components form this heterodimeric complex: kelch-like protein 
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3 and cullin. Kelch-like protein 3 recognizes the substrates, and cullin facilitates their 
ubiquitylation. Losing either one of these proteins confers a gain of function on WNKs 
and results in NCC and NKCC2 hyperactivity.20 
 The existence of multiple WNK isoforms accounts for their differing functions. 
The most significant and most puzzling is WNK4. In vitro studies of Xenopus laevis 
oocytes showed WNK4 inhibiting NCC by either directing it for lysosomal degradation 
or interfering with its processing in the Golgi apparatus.14,19,22,23 It was also found in the 
salt-resistant Sprague Dawley (SD) rats that a low-salt diet decreased WNK4 expression 
and increased expression of NCC mRNA, while a high-salt diet exerted the opposite 
effects.22,24 Therefore, it was perplexing when later in vivo studies painted WNK4 as a 
stimulator of NCC. Overactive WNK4 in vivo increased SPAK and OxSR1 
phosphorylation and caused a Gordon’s syndrome-like phenotype.25 Meanwhile, total 
loss of WNK4 decreased both NCC activity and blood pressure.17 To settle these 
conflicting functions, it has been hypothesized that the cellular environment modulates 
the function of WNK4.19 Angiotensin II (AII)-mediated increases in intracellular calcium 
seem to switch WNK4 from inhibitory to stimulatory actions. Other WNK isoforms may 
also have a similar influence.16 
 One of these isoforms is WNK1. A common form of WNK1 is a mutant in which 
not all of its exons have been spliced out. This long WNK1 (L-WNK1) powerfully 
activates SPAK by inhibiting WNK4 (which again suggests an inhibitory role for 
WNK4).19,26 L-WNK1 also forms homodimers and heterodimers with itself, WNK4, and 
WNK3 by interacting with the conserved HQ motifs located on the C-terminal sides. This 
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dimerization modulates their activities, but to what effect remains unclear. Another form 
of WNK1 is the kidney-specific WNK1 (KS-WNK1) which inhibits L-WNK1, thus 
inhibiting NCC.26 WNK3 is another important isoform that stimulates NCC. How it does 
this is not known, but the ratio of WNK3 to WNK4 appears to indicate whether NCC is 
being inhibited (a low ratio) or being stimulated (a high ratio).19  
 
 
Figure 2. Regulation of NCC. WNKs can regulate NCC by influencing its expression on 
the apical membrane (Type 1 regulation) and/or its level of phosphorylation (Type 2 
regulation). WNK1 stimulates NCC by either inhibiting WNK4 or stimulating SPAK. 
WNK4 may inhibit NCC by preventing its expression on the apical membrane or 
stimulate NCC by phosphorylating SPAK. Figure taken from Glover et al.14 
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SPAK and OxSR1   
WNKs can be potentially useful targets for drug therapy, but their pleiotropic 
functions and influence over multiple transporters may result in undesirable side effects. 
However, SPAK and OxSR1 may make excellent targets. Lying downstream of the 
WNKs, SPAK and OxSR1 are protein kinases that possess similar N-terminal catalytic 
domains and C-terminal regulatory domains25, and both can phosphorylate and activate 
NCC. Though SPAK and OxSR1 share similar structures and functions, differences do 
exist. SPAK occurs primarily in the DT to activate NCC. OxSR1 is there too, but it also 
works in the TAL to activate NKCC2.13,18 An in vivo study by Chu et al. demonstrated 
the power SPAK and OxSR1 wield in sodium transporter regulation. Mice with 
overactive WNK4 showed Gordon’s syndrome symptoms when OxSR1 was either 
present or knocked out. However, when overactive WNK4 was coupled with a SPAK 
knockout model, a normal phenotype was observed. Losing both OxSR1 and SPAK 
resulted in hypotension despite the overactive WNK4. This suggests that SPAK is the 
primary phosphorylator of NCC. OxSR1 can help compensate for the loss of SPAK, but 
on its own it fails to achieve the same levels of phosphorylation.16,25  
 
Table 1. Summary of in vivo kinase study by Chu et al.25 Overactive WNK4 increases 
NCC activity with or without OxSR1. Losing SPAK prevents WNK4 stimulation of 
NCC. Loss of both SPAK and OxSR1 results in hypotension.   
 
Mouse Model Phenotype 
Overactive WNK4 PHAII (hypervolemia, hypertension, 
hyperkalemia, increased renin) 
Overactive WNK4 + OxSR1 Knockout PHAII 
Overactive WNK4 + SPAK Knockout Normal phenotype 
Overactive WNK4 + OxSR1 Knockout + 
SPAK Knockout 
Hypotension, hypokalemia 
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The RAAS System 
An understanding of the regulation of NCC allows us to comprehend how 
extrarenal stimuli modulate NCC expression and contribute to SS hypertension. The 
sympathetic nervous system (SNS) is one such stimulus. It has been shown that increased 
activity of the efferent renal sympathetic nerves can work indirectly to increase sodium 
reabsorption.8,22 One way it does this is by vasoconstricting the afferent renal arterioles, 
which decreases the amount of sodium filtered. The SNS also stimulates the renin-
angiotensin-aldosterone system (RAAS).27 The RAAS works to retain sodium and water 
in the face of hypovolemia and/or hypotension. Sensing decreased tubular flow, the 
juxtaglomerular cells of the kidney release renin. Renin is then converted into angiotensin 
I and later into angiotensin II (AII) which acts on multiple levels to retain sodium.9 AII 
further vasoconstricts the renal arterioles7 and, as mentioned previously, is suspected of 
switching WNK4 from an inhibitor to a stimulator of NCC.24 Thus AII-mediated sodium 
retention relies on high salt intake and WNK4. If either of these two is lacking then the 
hypertensive effects of AII are attenuated.18,32  
 AII increases sodium retention a third way by stimulating aldosterone release.8,9 
Similar to AII, aldosterone increases sodium reabsorption in response to decreasing ECF 
sodium levels.21 It accomplishes this by binding to mineralocorticoid receptors (MR) in 
the distal nephron. The activated receptors increase the transcription of the kinase SGK1 
(serum/glucocorticoid-regulated kinase 1), which goes on to phosphorylate two serine 
residues near the carboxyl terminus of WNK4. This phosphorylation either activates 
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WNK4 or frees NCC from WNK4 suppression. Which one of these actions is the case is 
unclear.26  
 Because aldosterone powerfully stimulates NCC, it would be natural to assume 
that SS individuals would have higher aldosterone levels than SR ones. However, this is 
not so. Salt loading has been found to decrease aldosterone levels in both SS and SR 
persons.23 This does not mean that SGK1 cannot contribute to salt-sensitive hypertension. 
Rac1, a member of the Rho family of GTPases, can activate MRs independently of 
aldosterone.8 In SR individuals, salt intake decreases both aldosterone and Rac1 levels; 
thus MR activation is minimal. SS people also have lowered aldosterone in response to 
salt, but their Rac1 levels rise, leading to increased MR activation, SGK1 transcription, 
and NCC activity. This highlights the value that an MR blocker can bring to hypertension 
therapy.8,22  
 
The Sympathetic Nervous System 
 If chronically elevated aldosterone and AII are not a direct source of salt-sensitive 
hypertension, the question remains as to what is responsible. New studies indicate that in 
addition to indirectly increasing sodium reabsorption the SNS can directly increase 
sodium reabsorption by stimulating NCC in a pathway independent of AII, aldosterone, 
and renal hemodynamics.29–31 This was first suspected when it was found that SS 
individuals had higher plasma concentrations of norepinephrine (NE) than SR 
individuals.32 When later studies tested the effects of salt loading, both groups exhibited 
no differences in their sodium balance and had similar levels of AII and aldosterone. The 
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only difference was in their plasma NE levels which decreased in the SR group but 
increased in the SS group.33 The discovery of both alpha- and beta-receptors on kidney 
tubular cells reinforced the idea that the sympathetic nervous system can directly 
influence tubular function.34–36 Early renal denervation trials found that cutting the kidney 
off from efferent sympathetic influence produced a considerable and sustained drop in 
blood pressure in patients with resistant hypertension.27,37,38 This implies that aberrant 
SNS activity can contribute to the pathogenesis of salt-sensitive hypertension.      
 The dispersion of adrenergic receptors on the tubular cells of the kidney suggests 
that each part of the nephron has a unique response to sympathetic stimulation. Alpha1-
adrenergic receptors have been found to increase sodium reabsorption in the PT,38 beta1-
adrenergic receptors  have been found to stimulate the release of renin,39 and now studies 
have implicated the beta2-adrenergic receptors in the DT as accountable for increasing 
the activity of NCC.7,15,40 An early micropuncture study showed that the DT is responsive 
to beta agonists and antagonists. Isoproterenol, an agonist, increased sodium reabsorption 
in the DT, while propranolol, an antagonist, decreased sodium reabsorption.41 A few 
decades later a study by Mu et al.42 proposed an intracellular pathway. They observed 
that beta2-adrenergic receptor activation stimulated protein kinase A to phosphorylate 
histone deacetylase 8. Once phosphorylated, histone deacetylase 8 was unable to act on 
histones 3 and 4. Because they were still acetylated, histones 3 and 4 were able to bind to 
the promoter region of the WNK4 gene. As this was happening, glucocorticoid receptors 
(GR) in the DT were activated. These activated GRs, along with negative glucocorticoid 
response elements, also bound to the promoter region. WNK4 transcription dropped as a 
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result, and NCC was freed from inhibition. For this mechanism to increase blood 
pressure, GR activation and excessive salt intake had to be present. Losing either one of 
these conditions nullified the effect of beta2-receptor activation. On the other hand, MR 
activation and AII generation were not involved in this pathway.  
 
 
Figure 3. Actions of the renal sympathetic nervous system in response to salt. Salt-
sensitive individuals exhibit increased renal SNS activity in response to salt. This 
activates the beta2-adrenergic receptors in the DT, leading to inhibition of WNK4 
transcription, increased NCC activity, and ultimately hypertension. Figure taken from 
Fujita.22 
 
The pathway proposed by Mu et al. further implicates the sympathetic nervous 
system in the development of salt-sensitive hypertension and nominates the beta2-
adrenergic receptors as targets for therapeutic treatment.42 However, further experiments 
could expand the scope of this study. Mu et al. supported their hypothesis of the beta2-
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receptor-SPAK/OxSR1-NCC pathway using data collected from salt-resistant mice. The 
limitation of mice is that it is difficult to induce salt-sensitivity in them. To do so, Mu et 
al. had to perform bilateral adrenalectomy and challenge them with a high-salt diet and 
infusions of NE, propranolol, or isoproterenol.42 While this does not nullify their results, 
their proposed pathway would be further validated if it were demonstrated in an 
additional salt-resistant animal species.   
It should also be noted that not all researchers are in unanimous agreement on the 
specifics of this pathway. In replicating these experiments, Uchida et al. found no change 
in WNK4 mRNA, NCC, and pNCC (phosphorylated NCC) levels upon activation of the 
beta2-receptors.43 Ellison et al. were also unable to detect any changes in WNK4 mRNA 
levels in response to beta2-receptor activation.15 These results further emphasize the 
importance of testing this pathway in more than one animal species.  
 
Aims of the Present Study 
 The question our study proposes to answer is whether the sympathetic nervous 
system can generate salt-sensitive hypertension. If so, then we will test the hypothesis 
that it is mediated through dysregulation of the sodium-chloride cotransporter NCC. If 
this is true as well, then we will assess the role of beta-adrenergic receptors in this 
pathway. While answering these questions, we will perform our experiments in the 
Sprague-Dawley rat. Like mice, they are salt-resistant. However, by using them we will 
be expanding the scope of previous studies and establishing that the beta-receptor 
pathway proposed by Mu et al.42 is applicable in a salt-resistant animal species apart from 
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the mouse. In doing so we hope to demonstrate in the Sprague-Dawley rat that the 
sympathetic nervous system can contribute to the pathogenesis of salt-sensitive 
hypertension by dysregulating the activity of NCC through a beta-adrenergic pathway.  
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METHODS 
  
Animals 
 We used male Sprague-Dawley (SD) rats (270-300 g bodyweight; Harlan 
Laboratories, Inc., Indianapolis, IN, USA) for these experiments. Each rat was kept in its 
own cage where the environment was controlled in both temperature (range 68-79 °F) 
and humidity (range 30%-70%) and operated under a twelve-hour light/dark cycle. The 
SD rats underwent implantation of a subcutaneous osmotic minipump and were assigned 
to either a standard rodent diet (0.4% NaCl [0.174 mEq Na/kg]) or a high-salt diet (8% 
NaCl [1.378 mEq Na/kg]) for fourteen days. Both groups had ad libitum access to water. 
The Boston University School of Medicine Institutional Animal Care and Use Committee 
approved all of our protocols, and our procedures were conducted in compliance with the 
National Institutes of Health’s Guide for the Care and Use of Laboratory Animals. 
  
Surgical Procedures 
1. Subcutaneous Osmotic Minipump Implantation: All SD rats (except the naïve 
group) underwent subcutaneous osmotic minipump implantation. Animals 
were given 20 mg/kg of sodium methohexital intra-peritoneally (i.p.) to 
anesthetize them and were then implanted subcutaneously with an osmotic 
minipump (model 2ML2, Alzet, Palo Alto, CA, USA) in the subscapular 
region. After receiving the pumps, the animals were returned to their home 
cages.  
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2. Acute Femoral Vein, Artery, and Bladder Cannulation: After fourteen days of 
living on either a standard diet (0.4% NaCl) or a high-salt diet (8% NaCl), all 
animals underwent acute femoral vein, artery, and bladder cannulation. Again, 
20 mg/kg of sodium methohexital was given i.p. to anesthetize the animals. If 
necessary, an additional 10 mg/kg i.p. was administered. Cannulas were then 
inserted into the left femoral artery to measure blood pressure and heart rate, 
left femoral vein to administer saline and/or drugs intravenously (i.v.), and 
bladder to monitor renal function. Following surgery the rats recovered in 
Plexiglas holders and received an i.v. infusion of saline for two hours. This 
enabled the rats to regain full consciousness and allowed their cardiovascular 
and renal functions to stabilize. Their blood pressures and heart rates were 
constantly recorded by means of the femoral artery cannula using computer-
driven BIOPAC data acquisition software (BIOPAC, Goleta, CA, USA) 
connected to an external pressure transducer (model P23XL; Viggo 
Spectramed Inc., Oxnard, CA, USA).  
 
Chronic Experimental Treatment Groups 
1. Naïve Animals: Naïve SD rats were randomly assigned to receive either a 
standard diet (0.4% NaCl) or a high-salt diet (8% NaCl) for fourteen days 
(N=6/group). 
2. Isotonic Saline Infusion: SD rats were implanted with osmotic minpumps 
delivering a subcutaneous (s.c.) infusion of isotonic saline (flow rate 5 µL/h) 
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before being randomly assigned to either a standard diet (0.4% NaCl) or a 
high-salt diet (8% NaCl) for fourteen days (N = 5/group). 
3. Norepinephrine Infusion: SD rats were implanted with osmotic minipumps 
delivering an s.c. infusion of norepinephrine dissolved in isotonic saline (NE; 
600 ng/min; flow rate 5 µL/h) before being randomly assigned to either a 
standard diet (0.4% NaCl) or a high-salt diet (8% NaCl) for fourteen days (N 
= 6/group). 
4. DMSO/Saline Vehicle Infusion: SD rats were implanted with osmotic 
minipumps delivering an s.c. infusion of DMSO/isotonic saline (50:50 
solution; flow rate 5 µL/h) before being randomly assigned to either a 
standard diet (0.4% NaCl) or a high-salt diet (8% NaCl) for fourteen days (N 
= 6/group). 
5. NE + Hydrochlorothiazide (HCTZ) Infusion: SD rats were implanted with 
osmotic minipumps delivering an s.c. infusion of norepinephrine (NE 600 
ng/min; flow rate 5 µL/h) in combination with hydrochlorothiazide (HCTZ 4 
mg/kg/day; flow rate 5 µL/h) dissolved in DMSO/isotonic saline (50:50 
solution) before being randomly assigned to either a standard diet (0.4% NaCl) 
or a high-salt diet (8% NaCl) for fourteen days (N = 6/group). 
6. NE + Propranolol Infusion: SD rats were implanted with osmotic minipumps 
delivering an s.c. infusion of norepinephrine (NE; 600 ng/min; flow rate 5 
µL/h) in combination with the beta-adrenergic receptor antagonist propranolol 
(propranolol 10 mg/kg/day; flow rate 5 µL/h) dissolved in DMSO/isotonic 
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saline (50:50 solution) before being randomly assigned to either a standard 
diet (0.4% NaCl) or high-salt diet (8% NaCl) for fourteen days (N = 6/group).   
 
Acute Experimental Protocols 
After living on a standard diet (0.4% NaCl) or a high-salt diet (8% NaCl) for 
fourteen days, the SD rats were subjected to the following protocols. The protocols were 
performed consecutively in a single experiment.  
1. Blood Pressure Measurement: After a two-hour recovery period, the baseline 
mean arterial pressure (MAP; measured in mm Hg) of each rat was recorded 
continuously over a thirty-minute period using the femoral artery cannula. 
Baseline MAP was calculated as the overall average of the MAP during the 
thirty-minute period.  
2. Kidney Sodium Transporter Activity: After the MAP measurement, all rats 
received a one-hour control i.v. infusion of isotonic saline (flow rate 20 
µLmin) followed by a one-hour i.v. infusion of amiloride (2 mg/kg; 20 
µL/min) and finished with a one-hour i.v. infusion of amiloride (2 mg/kg; 20 
µLmin) combined with hydrochlorothiazide (2 mg/kg; 20 µL/min)23. Heart 
rate and MAP were continuously monitored during all three of the infusion 
periods, and the urine was collected in ten-minute intervals in order to assess 
peak natriuresis to i.v. amiloride or hydrochlorothiazide. 
3. Assessment of Beta-Receptor Blockade:  Upon completion of the kidney 
sodium transporter activity protocol, the NE + propranolol-infused rats were 
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given an i.v. bolus (7 µg) of the beta-agonist isoproterenol. The peak changes 
in blood pressure (peak ΔMAP) and heart rate (Δ heart rate) were measured in 
order to verify that propranolol successfully blocked the beta-receptors. Both 
peak ΔMAP and Δ heart rate were defined as the difference between the 
values of MAP/heart rate immediately before the rats began recovering from 
isoproterenol administration and the values of MAP/heart rate immediately 
before isoproterenol was first administered. Once the rats recovered, they 
underwent the autonomic function protocol in a manner similar to the other 
animal groups.  
4. Autonomic Function: Upon completion of the kidney sodium transporter 
activity protocol on all rats (and the assessment of beta-receptor blockade 
protocol on NE + propranolol-infused rats), an i.v. bolus of hexamethonium 
(30 mg/kg) was administered, and the peak response in mean arterial blood 
pressure (peak ΔMAP) was recorded. Peak ΔMAP was defined as the 
difference between the MAP immediately before the rats began recovering 
from hexamethonium administration and the MAP before hexamethonium 
was administered. Afterwards both kidneys were harvested from the rats and 
frozen at -80 °C for measurement of NCC proteins, SPAK, and OxSR1 in the 
outer cortex of the kidney.  
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Analytical Techniques 
Urine volume was measured gravimetrically with the assumption that 1 g = 1 ml. 
Flame photometry (model 943; Instrumentation Laboratory, Bedford, MA, USA) was 
used to measure the sodium concentration (in mM) in the urine. Natiruresis (UNaV) 
was calculated using the following equation: UNaV = (rate of urine excretion 
(µL/min) x sodium concentration (mmol/L))/1000. Peak natriuresis (peak ΔUNaV) 
was calculated by taking the average natriuresis of the last two ten-minute intervals of 
an infusion and subtracting it from the natriuresis of the first ten-minute interval after 
a drug was administered.  
   
Kidney Cortex Membrane Preparation 
The harvested kidneys were collected and stored at -80 °C upon completion of the 
acute experiment. The kidney cortex tissue (~200 mg) was homogenized on ice in a 
buffer (10 mM triethanolamine, 250 mM sucrose, 100 mM sodium azide (NaN3), 10 
mM phenylmethanesulfonylflouride (PMSF), and 1 mM leupeptin) using a handheld 
pestle. The tissue homogenate was centrifuged at 4,000 x g for ten minutes at 4 °C, 
and the resulting supernatant was collected and further centrifuged at 17,000 x g for 
an hour at 4°C. Afterwards the membrane pellet was resuspended in 300 µL of the 
homogenization buffer, and a bicinchroninic acid (BCA) assay was used to quantify 
the protein content. All membrane preparations were stored at -80 °C.  
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Determination of Renal Sodium Chloride Cotransporter, SPAK, and OxSR1 Levels 
 
Membrane preparations of kidney cortex tissue were loaded at a concentration of 
20 µg of protein per lane. Membranes were blocked in 5% milk for an hour and 
probed overnight at 4 °C with either anti-NCC (1:2000), anti-SPAK (1:2000), or anti-
OxSR1 (1:2000) antibodies in 0.5% phosphate-buffered saline with Tween 20 (PBS-
T). Afterwards the membranes were exposed to a secondary horseradish peroxidase 
donkey anti-rabbit IgG (H+L) (1:5000) in 0.5% PBS-T for an hour at room 
temperature. Chemiluminescence was used to visualize the bound antibodies. 
Densitometric analysis was performed using Quantity One software (Bio-Rad, 
Waltham, MA, USA), and band densities were normalized to β-actin (1:5000). 
 
Statistical Analysis 
Data were expressed as mean ± standard error of the mean (SEM). Differences 
among groups were assessed by a two-way analysis of variance (ANOVA), followed 
by a Tukey post-hoc test to compare variations between groups. Statistical analysis 
was carried out using the software program GraphPad Prism (v6; GraphPad Software, 
La Jolla, CA, USA). Statistical significance was defined as p < 0.05.  
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RESULTS 
 
 
Effect of Salt and Norepinephrine Infusion on Mean Arterial Pressure 
Because the sympathetic nervous system is suspected of playing a role in the 
pathogenesis of salt sensitivity, we first compared the mean arterial pressure (MAP) 
values of norepinephrine (NE)-infused Sprague-Dawley (SD) rats with those of naïve and 
saline (vehicle)-infused SD rats (Figure 4). Diet was also taken into consideration, with 
animals in each group subsisting on either a standard rodent diet (0.4% NaCl) or a high-
salt diet (8% NaCl).  
 
 
Figure 4. Mean arterial pressures of naïve, saline (vehicle), and NE-infused rats. 
Increased salt intake fails to increase the blood pressures of naïve and saline-infused rats. 
NE infusion elevates MAP. A high-salt diet exacerbates this effect. (*p < 0.05 vs. 
respective naïve group; τp < 0.05 vs. respective saline (vehicle) group; ϕp < 0.05 vs. NE + 
normal salt; mean ± SEM; N = 5-6.)    
  
  
  Because SD rats are naturally salt-resistant, a high-salt diet failed to significantly 
increase the MAP in naïve and saline-infused rats. Rats infused with NE experienced 
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elevated blood pressure while living on a standard diet. A high-salt diet intensified the 
hypertensive effect of NE.  
Effect of Salt and Norepinephrine on Response to Hexamethonium 
To determine how much of the elevated blood pressure was due to vascular 
vasoconstriction we administered an i.v. bolus of the ganglionic blocker hexamethonium 
and measured the peak changes in MAP (peak ΔMAP) across the six groups (Figure 5). 
 
Figure 5. Hexamethonium-induced depressions of MAP in naïve, saline, and NE-
infused rats. NE-infused rats experience the same response to hexamethonium regardless 
of their diet. (*p < 0.05 vs. respective naïve group; τp < 0.05 vs. respective saline group; 
mean ± SEM; N = 5-6.)   
 
 NE-infused rats on both a standard and high-salt diet displayed similar 
hexamethonium-evoked drops in MAP. Their responses exceeded those of the naïve and 
saline-infused rats on both standard and high-salt diets.  
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Effect of Salt and Norepinephrine on Sodium Transporter Activity 
 Because recent studies suspect that the sympathetic nervous system exerts some 
of its hypertensive effects by upregulating sodium transporter activity in the kidneys,15,42 
we investigated the activities of the epithelial sodium channel (ENaC) and the sodium-
chloride cotransporter (NCC). In order to assess sodium transporter activity, we 
administered infusions of specific sodium transporter blockers and measured their peak 
natriuretic responses (peak ΔUNaV).  
To determine ENaC activity, we gave the rats the ENaC antagonist amiloride 
(Figure 6).  
 
Figure 6. Natriuretic response to amiloride in naïve, saline, and NE-infused rats. 
NE-infused rats have a response to amiloride similar to the response of naïve rats. (*p  < 
0.05 vs. respective normal salt group; mean ± SEM; N = 5-6.) 
  
 In native SD rats a high-salt diet has been found to downregulate ENaC; thus 
amiloride only elicits a mild natriuresis in animals on a high-salt diet. However, as shown 
in Figure 6, naïve and NE-infused rats had a large response to amiloride when on a 
	  26 
standard diet (indicating high ENaC activity) and a blunted response when on a high-salt 
diet (indicating low ENaC activity).  
 NCC activity was measured by i.v. infusion of the NCC antagonist 
hydrochlorothiazide (HCTZ) (Figure 7).  
 
Figure 7. Natriuretic response to HCTZ in naïve, saline, and NE-infused rats. NE-
infused rats experience no salt-induced suppression of NCC activity. (*p < 0.05 vs. 
respective normal salt group, τp < 0.05 vs. respective saline group; mean ± SEM; N = 5-
6.) 
  
  NCC activity was downregulated in naïve and saline-infused rats living on a high-
salt diet. However, in the presence of NE, a high-salt diet failed to downregulate NCC 
activity.  
Effect of Norepinephrine on NCC, SPAK, and OxSR1 Levels 
After determining the degree of NCC activity, we quantified the expression of 
NCC proteins in the kidney. To do this, we harvested the kidney cortexes of the saline-
infused and NE-infused rats and measured their levels of NCC expression (Figure 8).  
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Figure 8. Expression of NCC proteins in the kidney cortex of saline and NE-infused 
rats. A high-salt diet results in no downregulation of NCC proteins in NE-infused rats. 
(ODU, optical density units; *p < 0.05 vs. saline + normal salt group; mean ± SEM; N = 
5-6.) 
 
A high-salt diet decreased the expression of NCC proteins in the saline-infused 
rats. However, infusion of NE prevented excessive salt from downregulating NCC 
protein expression. As a follow-up we measured the levels of SPAK and OxSR1, two 
known phosphorylators of NCC (Figures 9 and 10). 
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Figure 9. Expression of SPAK in the kidney cortex of saline and NE-infused rats. 
SPAK drops in response to excess salt in saline-infused rats. A high-salt diet fails to 
downregulate SPAK in NE-infused rats. (ODU, optical density units; *p < 0.05 vs. 
respective normal salt group; τp < 0.05 vs. respective saline group; mean ± SEM; N = 5-
6.)  
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Figure 10. Expression of OxSR1 in the kidney cortex of saline and NE-infused rats. 
NE significantly increases the expression of OxSR1 in rats living on both standard and 
high-salt diets. (ODU, optical density units; *p < 0.05 vs. respective saline group; mean ± 
SEM; N = 5-6.) 
  
In saline-infused rats a high-salt diet significantly downregulated SPAK but not 
OxSR1. NE-infused rats experienced no salt-induced suppression of SPAK and OxSR1 
and exhibited elevated levels of OxSR1.  
 
Effect of Norepinephrine and Hydrochlorothiazide Co-Infusion on Mean 
Arterial Pressure 
 
 NCC is believed to command a significant influence on blood pressure as a result 
of the hypertensive effects observed when it is overactive (Gordon’s syndrome) and the 
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hypotensive effects when it is impaired (Gitelman’s syndrome)14,42. To test this influence 
we gave SD rats a co-infusion of NE combined with the NCC antagonist 
hydrochlorothiazide (HCTZ), assigned them to either a standard diet (0.4% NaCl) or a 
high-salt diet (8% NaCl) for two weeks and compared their blood pressures (MAP 
values) with those of 50:50 DMSO/saline-infused (control) and NE-infused rats (Figure 
11).  
  
Figure 11. Mean arterial pressures of DMSO, NE, and NE + HCTZ-infused rats. 
Co-infusion of HCTZ with NE eliminates the salt-sensitive component of NE-mediated 
hypertension. (*p < 0.05 vs. respective normal salt group, τp < 0.05 vs. respective 
DMSO/saline group, ϕp < 0.05 vs. NE + high salt group; mean ± SEM; N = 6.)  
 
 
 Infusion of norepinephrine significantly increased blood pressure, and excess salt 
exacerbated this effect. The addition of HCTZ produced a heightened blood pressure 
similar to that of the NE-infused rats living on a standard diet. Diet did not cause a 
noteworthy variation of blood pressure within the NE + HCTZ group.  
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Effect of Norepinephrine and Hydrochlorothiazide Co-Infusion on the Response to 
Hexamethonium   
To determine the extent of the contribution of vascular vasoconstriction to the 
blood pressures of DMSO, NE, and NE + HCTZ-infused rats, we gave them an i.v. bolus 
of hexamethonium and measured their peak depressions in MAP (peak ΔMAP) (Figure 
12).  
 
Figure 12. Hexamethonium-induced depressions of MAP in DMSO, NE, and NE + 
HCTZ-infused rats. NE + HCTZ-infused rats on a standard diet have a response to 
hexamethonium similar to the control DMSO-infused rats. A high-salt diet in NE+HCTZ 
animals leads to a heightened response resembling the NE-infused rats. (*p < 0.05 vs. 
respective DMSO vehicle group; mean ± SEM; N = 6.) 
 
  
 NE + HCTZ co-infusion caused the rats on a standard diet to have a response to 
hexamethonium similar to the responses seen in the DMSO-infused rats. By contrast, a 
high-salt diet led the NE + HCTZ-infused rats to respond in a manner comparable with 
the NE-infused rats.  
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Effect of Norepinephrine and Hydrochlorothiazide Co-Infusion on Sodium 
Transporter Activity 
To ascertain the effects of chronic NE + HCTZ co-infusion on ENaC and NCC 
activity, we gave the rats infusions of amiloride and HCTZ and measured their peak 
natriuretic responses (peak ΔUNaV) (Figures 13 and 14).  
 
Figure 13. Natriuretic response to amiloride in DMSO, NE, and NE + HCTZ-
infused rats. NE and NE + HCTZ-infused rats experience diet-evoked suppression of 
ENaC activity. (*p < 0.05 vs. respective normal salt group; mean ± SEM; N = 6.)   
 
 
Figure 14. Natriuretic response to HCTZ in DMSO, NE, and NE + HCTZ-infused 
rats.  Rats co-infused with NE and HCTZ have a significantly diminished natriuretic 
response to HCTZ compared with DMSO and NE-infused rats. (*p <0.05 vs. respective 
normal salt group, τp < 0.05 vs. respective DMSO/saline group, ϕp < 0.05 vs. respective 
NE group; mean ± SEM; N = 6.) 
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NE and NE + HCTZ-infused rats exhibited similar natriuretic responses to 
amiloride while on a standard diet and experienced an attenuated natriuresis when placed 
on a high-salt diet. These groups, however, differed in their responses to HCTZ. Rats 
infused solely with NE had a high natriuresis regardless of diet, whereas the co-infusion 
of HCTZ with NE led to severely blunted natriuretic responses regardless of diet.  
 
 
Effect of Norepinephrine and Propranolol Co-Infusion on Mean Arterial Pressure  
 
Recent studies claim that activation of the beta2-adrenergic receptors in the distal 
tubules upregulates NCC, SPAK, and OxSR1.15,42 To test this claim we implanted SD 
rats with osmotic minipumps delivering a simultaneous infusion of the beta-blocker 
propranolol with NE. After a two-week period of subsisting on either a standard diet 
(0.4% NaCl) or a high-salt diet (8% NaCl), the NE + propranolol-infused rats exhibited a 
blockage of their beta-receptors as a result of the chronic infusion of propranolol (see 
isoproterenol testing in the Appendix). At this time we compared the blood pressures 
(MAP values) of these rats with the blood pressures of their saline and NE-infused 
counterparts (Figure 15).  
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Figure 15. Mean arterial pressures of saline, NE, and NE + propranolol-infused 
rats. Propranolol eliminates NE-mediated hypertension. (*p < 0.05 vs. respective saline 
group; τp <  0.05 vs. respective normal salt group; Φp < 0.05 vs. respective NE group; 
mean ± SEM; N = 6.) 
 
The addition of propranolol abolished the hypertensive effects of norepinephrine. 
Moreover, diet caused no significant difference in the blood pressures within the NE + 
propranolol-infused rats. 
 
Effect of Norepinephrine and Propranolol Co-Infusion on Response to 
Hexamethonium    
 
To quantify the amount of vascular vasoconstriction resulting from co-infusion of 
NE and propranolol, we administered hexamethonium to the rats and measured their peak 
drop in MAP (peak ΔMAP)  (Figure 16).  
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Figure 16. Hexamethonium-induced depressions of MAP in saline, NE, and NE + 
propranolol-infused rats. Co-infusion of NE and propranolol results in a smaller 
response to hexamethonium than observed for the saline and NE-infused rats. (*p < 0.05 
vs. respective saline group, τp < 0.05 vs. respective NE group; mean ± SEM; N = 6.)   
 
 
 Because propranolol blocks all beta-receptors, including those located on the 
vasculature, NE + propranolol-infused rats exhibited the smallest drop in MAP compared 
with saline and NE-infused rats.  
 
Effect of Norepinephrine and Propranolol Co-Infusion on Sodium Transport 
Activity 
 
To determine the level of sodium transporter activity in the NE + propranolol-
infused rats, we again used amiloride and HCTZ to gauge ENaC and NCC activity, 
respectively. Their amiloride-evoked natriuresis (peak ΔUNaV) followed the same trend 
as seen in NE-infused rats; namely, a standard diet produced a high response, and a high-
salt diet produced an attenuated response (Figure 17).   
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Figure 17. Natriuretic response to amiloride in saline, NE, and NE + propranolol-
infused rats. NE + propranolol-infused rats have a response to amiloride similar to those 
found in NE-infused rats. (*p < 0.05 vs. respective normal salt group; mean ± SEM; N = 
6.) 
  
Propranolol infusion hardly affected the response of the rats to HCTZ. The NE + 
propranolol-infused rats on a standard diet had a natriuresis similar to those seen in the 
saline groups. A high-salt diet failed to downregulate their natriuretic response, which 
resembled that belonging to the NE-infused rats (Figure 18).  
Figure 18. Natriuretic response to HCTZ in saline, NE, and NE + propranolol-
infused rats. NE + propranolol-infused rats exhibit a natriuretic response to HCTZ that 
refuses to be downregulated by excess salt. (*p <0.05 vs. respective saline group, τp < 
0.05 vs. respective normal salt group; mean ± SEM;  N = 6.) 
 
τ	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Effect of Norepinephrine and Propranolol Co-Infusion on NCC, SPAK, and OxSR1 
Levels 
 
 After measuring their natriuresis, we harvested the kidney cortexes of the NE + 
propranolol-infused rats, quantified their expression of NCC proteins, and compared 
them with those of the saline and NE-infused rats (Figure 19). 
 
 
Figure 19. Expression of NCC proteins in the kidney cortex of saline, NE, and NE + 
propranolol-infused rats. NE + propranolol-infused rats on a high-salt diet show a 
lower level of NCC protein expression compared with the NE-infused rats. (ODU, optical 
density units; Φp < 0.05 vs. respective NE group; mean ± SEM; N = 6.) 
 
 	   Previously we found that infusion of NE alone prevented the salt-evoked 
suppression of NCC protein expression. However, the addition of propranolol resulted in 
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a significant decrease in NCC protein expression in response to a high-salt diet. To 
explore this further we measured the levels of SPAK and OxSR1 (Figures 20 and 21).   	  
	  
Figure 20. Expression of SPAK in the kidney cortex of saline, NE, and NE + 
propranolol-infused rats. Rats co-infused with NE and propranolol exhibit attenuated 
levels of SPAK expression compared with NE-infused rats. (ODU, optical density units; 
*p < 0.05 vs. respective normal salt group; τp < 0.05 vs. respective saline group; Φp < 
0.05 vs. respective NE group; mean ± SEM; N = 6.) 
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Figure 21. Expression of OxSR1 in the kidney cortex of saline, NE, and NE + 
propranolol-infused rats. Rats infused with NE and propranolol have a lower 
expression of OxSR1 compared with NE-infused rats. (ODU, optical density units; Φp < 
0.05 vs. respective NE group; mean ± SEM; N = 6.) 
  
Blocking the beta-receptors led the NE + propranolol-infused rats to have 
significantly lower levels of SPAK and OxSR1 than observed in the NE-infused rats, 
regardless of their diet.  
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DISCUSSION 	  	   	  
Key Findings	   in Norepinephrine-Infused Rats 
 
 Our results further support the contribution of the sympathetic nervous system 
(SNS) in the development of salt-sensitive hypertension. Chronic infusion of 
norepinephrine (NE) generated hypertension in the classically salt-resistant Sprague-
Dawley (SD) rat, and a high-salt diet magnified this effect. However, this rise in blood 
pressure cannot be attributed to renal mechanisms alone. Because the osmotic-mini 
pumps implanted in the rats were delivering NE on a systemic level, the observed effects 
were not the same as they would have been if NE was solely being produced locally at 
the kidneys through the renal efferent sympathetic nerve terminals.31,39 The ganglionic 
blocker hexamethonium allowed us to determine how much of the hypertension was due 
to vasoconstriction of the vasculature. We found that although the NE-infused rats on a 
high-salt diet had a greater MAP than their standard diet counterparts, the responses of 
both groups to hexamethonium were nearly identical. This indicated that the greater MAP 
in the high-salt group was due to more than just changes in vascular tone. 
 We then used amiloride and hydrochlorothiazide (HCTZ) to gauge the activity of 
the sodium transporters ENaC and NCC, respectively. Both naïve and NE-infused rats 
demonstrated decreased natriuretic responses to amiloride when placed on a high-salt 
diet, implying that increased sympathetic nervous system activity did not interfere with 
diet-evoked suppression of ENaC. However, when we gave the rats HCTZ, only the 
naïve and saline-infused rats experienced a high-salt mediated attenuation in their 
	  41 
natriuretic responses. Rats infused with NE exhibited a natriuretic response to HCTZ that 
could not be suppressed by a high-salt diet. Also for the NE-infused rats, we found that a 
high-salt diet failed to downregulate the expression of NCC and its phosphorylators 
SPAK and OxSR1. Therefore, it appears that chronic norepinephrine infusion, in 
mimicking overactive SNS activity, impedes the downregulation of both NCC function 
and expression during periods of excessive salt consumption.  
 
The Sympathetic Nervous System Dysregulates NCC When Contributing to Salt-
Sensitive Hypertension  
 
 To confirm that NCC is the primary transporter which the SNS dysregulates when 
contributing to salt-sensitive hypertension, we chronically antagonized NCC by co-
infusing SD rats with NE and HCTZ. As a result of this treatment, rats on a standard diet 
developed similar blood pressures to those of the NE-infused rats subsisting on a standard 
diet, but rats on a high-salt diet failed to exhibit the significantly increased pressures 
shown by their NE-infused counterparts. These trends suggested that antagonizing NCC 
eliminated the salt-sensitive component of NE-mediated hypertension. Rats co-infused 
with NE and HCTZ also displayed amiloride-evoked natriureses similar to those of the 
NE-infused rats. Thus blocking NCC did not prevent the salt-induced suppression of 
ENaC. Based on our animal model, we can surmise that excessive SNS activity 
dysregulates NCC to drive the development of salt-sensitive hypertension.  
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Propranolol Partially Counters the Effects of Norepinephrine Infusion 
 
 
Our data in part support the propositions of Mu and Ellison that the SNS activates 
the beta-adrenergic receptors to dysregulate NCC function and expression.15,42 When SD 
rats were co-infused with NE and the beta-antagonist propranolol, no significant rise in 
blood pressure occurred. Curiously, propranolol did not correct the dysregulation of NCC 
activity. Despite their beta-receptors being blocked, NE + propranolol-infused rats 
reacted with a heightened natriuresis to HCTZ similar to the response in the NE-infused 
rats. However, upon quantifying the expression of NCC, SPAK, and OxSR1 in the 
kidney, we found that NE and propranolol co-infusion substantially lowered the 
expression of all proteins compared with NE infusion alone. Since our measurement of 
NCC proteins did not differentiate between phosphorylated and non-phosphorylated 
states, it is possible that in the NE + propranolol-infused rats, all of the observed NCC 
proteins were phosphorylated, allowing function to remain high despite lowered protein 
count. The implications of this are two-fold: (1) beta-adrenergic receptor activation can 
prevent the salt-induced downregulation of NCC activity and expression of its proteins, 
SPAK, and OxSR1, and (2) NE may not solely rely on the beta-receptors to keep NCC 
activity high. 
 
Possible Influence of the Alpha-Adrenergic Receptors 
 The study by Mu and colleagues did not investigate the role of the alpha-
adrenergic receptors in the regulation of NCC.42 Previous studies have already shown that 
the alpha-receptors can facilitate sodium retention either by increasing renin release or by 
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directly stimulating sodium reabsorption in the proximal tubules.34,39 Our chief concern 
lies in their possible actions in the distal tubules (DTs). The distribution of alpha- and 
beta-adrenergic receptors in the DT cells varies. Some cells only have beta2-receptors; 
others have a mix of alpha-, beta1-, and beta2-receptors.39 When we co-infused rats with 
NE and propranolol, expression of NCC proteins, SPAK, and OxSR1 dropped, yet NCC 
activity remained at a level comparable with that of the NE-infused rats. We hypothesize 
that the alpha-receptors may be responsible for this action by operating through a WNK4-
dependent process, which is independent of the beta-receptors and SPAK/OxSR1 (Figure 
22). 
 
  
Figure 22. Possible alternative adrenergic influence on NCC. Beta-adrenergic 
receptors may not be the only conduit through which norepinephrine affects NCC. The 
alpha-receptors may be able to prevent the downregulation of NCC activity through a 
WNK4-dependent process. 
 
It should be mentioned that Ellison and coworkers did investigate the actions of 
the alpha-receptors on NCC activity. In this study mice were given either an alpha- or 
beta-agonist and had their levels of phosphorylated NCC (pNCC) measured thirty 
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minutes later. The beta-agonist group displayed a significant increase in pNCC, while the 
alpha-agonist group did not. When the mice were given both alpha- and beta-agonists 
simultaneously, they exhibited the greatest elevation of pNCC, which suggests a 
synergistic interaction between the two receptors.15 What concerns us in this experiment 
is that the alpha-receptors were only tested under acute conditions, and whether these 
results are applicable to a chronic model is unclear.   
 
Limitations of Study and Future Directions  
 Although our study generated useful data, the work lacks a firm grasp on the role 
of the alpha-adrenergic receptors during the regulation of NCC under conditions of 
chronic NE elevation. Future experiments could address this issue by chronically co-
infusing the rats with NE and the alpha-antagonist prazosin. In addition, because 
propranolol is a non-specific beta-antagonist, this study did not differentiate the effects of 
the beta1-receptors from those of the beta2-receptors. Chronically infusing the rats with 
NE and the beta1-antagonist atenolol could remedy this situation in future work.  
 Our study examined how elevated NE coupled with a high-salt diet induced salt-
sensitive hypertension in the salt-resistant Sprague-Dawley rat. We also found that 
activation of a beta-receptor-SPAK/OxSR1-NCC pathway led to the inability of excess 
salt to downregulate the expression of NCC proteins, SPAK, and OxSR1. However, our 
study, along with the work of Mu and Ellison,15,42 has only looked at the beta-receptor 
pathway in salt-resistant animal species. It would be interesting to determine if this 
pathway exists in a naturally salt-sensitive species such as the Dahl Salt-Sensitive rat. If 
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variances in the pathway do exist between the two animal models, this would emphasize 
the importance of the pathway as a therapeutic target in the treatment of salt-sensitive 
hypertension. 
 
Conclusion 
In conclusion, our study further demonstrates that elevated sympathetic nervous 
system (SNS) activity can give rise to salt-sensitive hypertension. Whereas the 
experiments led by Mu and Ellison induced salt sensitivity in the salt-resistant mouse 
model,15,42 we were able to do the same in the naturally salt-resistant Sprague-Dawley rat 
without the aid of bilateral adrenalectomy. In an attempt to mimic the actions of an 
overactive sympathetic nervous system, we chronically infused the rats with 
norepinephrine and found that it generated salt-sensitive hypertension to a certain extent 
by preventing the diet-evoked suppression of both NCC activity and the expression of 
NCC proteins, SPAK, and OxSR1. To see if NE brought about these changes through a 
beta-adrenergic receptor pathway, we co-infused the rats with NE and the beta-antagonist 
propranolol. This condition abolished the hypertensive influence of NE and attenuated 
the expression of NCC proteins, SPAK, and OxSR1. However, NCC activity remained 
elevated. Thus we can say that our data partially support the claims of Mu and Ellison. It 
does appear that the SNS can dysregulate NCC by activating the beta-receptors. The 
inability of beta-antagonism to lower NCC activity suggests that NE does not rely solely 
on the beta-receptors to affect NCC. The presence of alpha-adrenergic receptors in the 
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distal tubules implies that NE may activate them to affect NCC function and expression, 
and future studies will investigate this mechanism.  
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APPENDIX 
 
The inability of isoproterenol to significantly increase both blood pressure and 
heart rate for NE + propranolol-infused rats indicated that chronic infusion of propranolol 
had succeeded in blocking the beta-adrenergic receptors (Figures A1 and A2). 
Figure A1. Isoproterenol-evoked changes in the mean arterial pressure of NE + 
propranolol-infused rats. Isoproterenol fails to drastically increase the mean arterial 
pressure in rats co-infused with NE and propranolol. (MAP, mean arterial pressure; mean 
± SEM; N = 6.) 
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Figure A2. Isoproterenol-evoked changes in the heart rate of NE + propranolol-
infused rats. Isoproterenol fails to significantly increase heart rate in NE + propranolol-
infused rats. (BPM, beats per minute; mean ± SEM; N = 6.) 
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